News

b

b

Current News in Drug Discovery

RSS Nature Reviews Drug Discovery
  • Novel drug treatments for schizophrenia January 8, 2026
    Nature Reviews Drug Discovery, Published online: 08 January 2026; doi:10.1038/s41573-025-01335-wFor over 70 years, almost every drug approved for schizophrenia has modulated dopamine signalling, thus only addressing some symptoms and having notable side effects. Here, Coyle and Paul discuss drugs with promising new mechanisms under development for schizophrenia, including those targeting glutamatergic and cholinergic signalling.
    Joseph T. Coyle
  • Prime editing to suppress nonsense mutations January 6, 2026
    Nature Reviews Drug Discovery, Published online: 06 January 2026; doi:10.1038/d41573-026-00002-yPrime editing to suppress nonsense mutations
    Sarah Crunkhorn
  • Pharmacological targeting of the JAK–STAT pathway: new concepts and emerging indications January 5, 2026
    Nature Reviews Drug Discovery, Published online: 05 January 2026; doi:10.1038/s41573-025-01336-9The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway mediates cellular responses to cytokines and growth factors, and its dysregulation plays a role in various disorders including autoimmune diseases, cancers and neurodegenerative disorders. This Review provides an overview of JAK–STAT signalling and discusses current […]
    Teemu Haikarainen
  • Promoting prostaglandin signalling for joint repair in osteoarthritis January 5, 2026
    Nature Reviews Drug Discovery, Published online: 05 January 2026; doi:10.1038/d41573-025-00209-5Promoting prostaglandin signalling for joint repair in osteoarthritis
    Katie Kingwell
  • 2025 FDA approvals January 2, 2026
    Nature Reviews Drug Discovery, Published online: 02 January 2026; doi:10.1038/d41573-026-00001-zThe US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.
    Asher Mullard
  • Analysis of phase II and phase III clinical trial terminations from 2013 to 2023 December 18, 2025
    Nature Reviews Drug Discovery, Published online: 18 December 2025; doi:10.1038/d41573-025-00208-6Analysis of phase II and phase III clinical trial terminations from 2013 to 2023
    Heather Bowling
  • Trends in target novelty in oncology R&D December 17, 2025
    Nature Reviews Drug Discovery, Published online: 17 December 2025; doi:10.1038/d41573-025-00199-4Trends in target novelty in oncology R&D
    Jack Cuthbertson
  • FDA approves first gene therapy from a non-profit organization, but pricing and access questions remain December 17, 2025
    Nature Reviews Drug Discovery, Published online: 17 December 2025; doi:10.1038/d41573-025-00207-7FDA approves first gene therapy from a non-profit organization, but pricing and access questions remain
    Asher Mullard

Vitreon America™ Launches Botanicopeia™ Database and Federal Government Services at NIH Festival+

 BETHESDA, MD, September 17, 2016 − Vitreon America, Inc.™ participated this week in the National Institute of Health (NIH) Intramural Research Program’s 30th Annual NIH Research Festival which was held September 15-16, 2016 at the NIH Bethesda, Maryland campus.

The Festival included plenary sessions, symposia, exhibits, poster sessions and tours designed to encourage sharing and learning about the exciting research taking place on NIH campus.

Vitreon America™ was selected by the Technical Sales Association (TSA) which sponsors the Research Festival Exhibit, to launch its state-of-the-art Phytochemical and Ethnobotanical database subscription services, Botanicopeia™.

Attending on behalf of Vitreon America™
were Michael Megginson, VP of Business Development (left) and Jorgen Sandberg,
CEO (right).

Vitreon America was pleased to see the interest from the NIH Institutions to utilize the Botanicopeia™ database subscriptions with many NIH researchers expressing interest in considering the Vitreon America Botanical Research Analytic services as well to optimize the Botanicopeia™ database.

Based on the NIH researchers feedback, Vitreon America has established a Botanicopeia™ database subscription service agreement and subscription service with botanical research analytic services through Marshall Communications Corporation, www.marshallcomm.com.

Vitreon America services are available through Marshall Communications Corporation (VOSB) on NIH’s Information Technology Acquisition and Assessment Center’s (NITAAC)- Government-wide Acquisition Contract (GWAC) vehicle. [Prime Contract Holder #HHSN316201500063W]

Vitreon America™ was established with the goal of commercializing their Botanicopeia™ database and botanical research analytic services for development of botanicals and phytochemicals in the creation of new medicinal products by Vitreon America Clients.

To find out more about our Services please contact us for assistance at 1-888-214-2584 or at info@vitreonamerica.com

About Vitreon America™

Vitreon AmericaTM was formed with the goal of disseminating their BotanicopeiaTM database to encourage the increased use of botanicals and phytochemicals in the creation of new medicines.

Contact Vitreon America, Inc.

Vitreon America Botanical Research Center @ Hopkins Johns Hopkins University

MCC 9601 Medical Center Drive, Suite 221
Rockville, Maryland 20850

+1-888-214-2584

j.shaver@advasur.com